Abstract Coronavirus disease 2019 (COVID-19) has resulted in a global pandemic. Most
COVID-19 patients are asymptomatic or have flu-like symptoms. However, around 15% of …

Antiphospholipid antibodies (aPL) are mandatory for the diagnosis but are also a risk factor
for the antiphospholipid syndrome (APS) clinical manifestations. Lupus anticoagulant (LA) …

Background Despite expansion in the 2006 Sydney antiphospholipid syndrome (APS)
classification criteria to include IgG/IgM anti-β2-glycoprotein (aβ2GPI) antibodies in addition …

Abstract Purpose of Review To review the recent available evidence on epidemiology,
pathogenesis, clinical phenotypes, and management of antiphospholipid syndrome (APS) …

Background Antiphospholipid syndrome (APS) is a multisystemic autoimmune disorder
characterized by thrombotic events and/or gestational morbidity in patients with …

Antibodies to phospholipids (aPL) and associated proteins are a hallmark in the diagnosis of
anti-phospholipid syndrome (APS). Those included in the classification criteria are the lupus …

Antiphospholipid syndrome (APS) is an autoimmune prothrombotic disease characterized
by thrombosis and/or pregnancy complications caused by antiphospholipid antibodies …

High prevalence of both criteria and extra-criteria antiphospholipid antibodies (aPL) has
been reported in COVID-19 patients. However, the differences in aPL prevalence decreased …

Background Anti‐phosphatidylserine prothrombin antibodies (aPSPT) are reported to be
highly associated with the lupus anticoagulant (LAC) in established antiphospholipid …

Introduction Lupus anticoagulant (LA) testing is commonly performed within hemostasis
laboratories, and the ACL TOP 50 family of instruments represent a new “single platform” of …